2024/06/25 更新

写真a

キシダ　ユウヤ
岸田　侑也
Kishida Yuya
所属
付属病院 血液内科 助教
職名
助教
外部リンク

論文

  • Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less. 国際誌

    Atsushi Marumo, Ikuko Omori, Shuhei Tara, Yuki Otsuka, Ryosuke Konuma, Hiroto Adachi, Atsushi Wada, Yuya Kishida, Tatsuya Konishi, Akihito Nagata, Yuta Yamada, Ryohei Nagata, Yuma Noguchi, Takashi Toya, Aiko Igarashi, Yuho Najima, Takeshi Kobayashi, Hiroki Yamaguchi, Koiti Inokuchi, Hisashi Sakamaki, Kazuteru Ohashi, Noriko Doki

    Asia-Pacific journal of clinical oncology   18 ( 5 )   e507-e514   2022年10月

    　詳細を見る

    記述言語：英語   掲載種別：研究論文（学術雑誌）  

    Cyclophosphamide (CY)-induced cardiotoxicity involves rare lethal complications. We previously reported the cardiac events of 811 allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients; 12 out of 811 recipients (1.5%) developed fatal heart failure. The mortality rate was also very high (91.6%, 11/12). CY dose (200 mg/kg or more) was reported as the independent risk factor. The main disease in patients treated with 200 mg/kg or more of CY was severe aplastic anemia (AA). Therefore, we reduced the dose of CY during conditioning for AA (from 200 to 100 mg/kg), and then we analyzed the clinical features of 294 patients who received a total dose of at least 100 mg/kg of CY. We also compared the clinical features between the current study and our previous study. The proportion of patients treated with at least 200 mg/kg of CY was reduced from 4.2% to 0%. However, CY-induced heart failure occurred in four of the 294 patients (1.4%), which was similar to the finding reported in our previous study (1.5%). Two of these four patients received a post-transplant CY (PTCy) regimen (CY 100 mg/kg). All four patients were treated in the cardiac intensive care unit (C-ICU), and two patients survived. In summary, even the CY dose of 120 mg/kg or less would cause cardiotoxicity. We should also carefully monitor patients treated with PTCy, considering the possibility of CY-induced cardiotoxicity. Early diagnosis and ICU management have contributed to improved outcomes.

    DOI： 10.1111/ajco.13674

    PubMed

    researchmap

MISC

  • SARS-CoV-2感染を契機に発症した自家末梢血幹細胞移植後の間質性肺炎の1例

    木村 光利, 松木 覚, 三上 恵莉花, 磯 博和, 久金 翔, 渥美 健一郎, 岸田 侑也, 永田 耕治, 清家 正博, 廣瀬 敬

    日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集   182回・251回   38 - 38   2022年9月

    　詳細を見る

    記述言語：日本語   出版者・発行元：日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

    researchmap

  • 高度な骨髄線維化を来した骨髄原発大細胞型B細胞性リンパ腫の1例

    菅原 眞衣, 岸田 侑也, 永田 安伸, 脇田 知志, 山口 博樹

    臨床血液   63 ( 5 )   500 - 500   2022年5月

    　詳細を見る

    記述言語：日本語   出版者・発行元：(一社)日本血液学会-東京事務局  

    researchmap